Ibogaine is known to produce auditory hallucination, a auditory effect. Auditory hallucination is the perception of sounds that have no external source — hearing music, voices, environmental noises, or abstract sonic phenomena that exist entirely within the mind. These range from faint, ambiguous whispers at the edge of perception to fully formed, complex musical compositions or conversational speech that can feel completely real and externally sourced.
From a first-person perspective, auditory hallucinations manifest as sounds that feel genuinely external — as though they originate from somewhere in the physical environment — despite having no corresponding source. One may hear faint music playing from another room, indistinct conversational murmuring, environmental sounds like running water or wind, or entirely novel sonic phenomena such as buzzing, chiming, or crystalline tones. At higher intensities, full musical compositions may be perceived with remarkable complexity and fidelity, sometimes in genres or styles the listener has never heard before. Voices may speak coherent sentences, sometimes addressing the user directly, though insight is usually maintained that these are drug-induced.
At threshold levels, auditory hallucinations present as vague, ambiguous sounds — one might question whether a faint sound was real or imagined. At light to moderate intensities, the hallucinations become more distinct: identifiable snippets of music, recognizable whispered words, or phantom environmental sounds like doorbells or phone notifications. At strong doses, fully formed auditory experiences emerge — entire songs with lyrics, complex conversations, or rich environmental soundscapes that are indistinguishable from reality until one actively questions their origin. At overwhelming levels, the hallucinated audio can completely dominate the perceptual field, making it difficult to distinguish real from imagined sound.
Musical hallucinations involve hearing melodies, harmonies, or complete compositions, often novel and not drawn from memory.Verbal hallucinations consist of hearing words or sentences — these may be fragments, gibberish, or coherent speech.Environmental hallucinations replicate familiar ambient sounds (rain, traffic, appliances).Abstract sonic hallucinations produce sounds without clear real-world analogues — geometric buzzing, fractal tones, or sounds that seem to have visual or spatial properties. Auditory hallucinations can beopen-eye (perceived as external) orclosed-eye (perceived as internal, mind's-ear phenomena).
Auditory hallucinations arise from spontaneous activation of auditory cortical areas in the absence of corresponding external stimuli. Serotonergic psychedelics facilitate this through 5-HT2A agonism, which increases spontaneous neural firing in auditory association cortex and disrupts the brain's ability to distinguish internally generated signals from external input. Dissociatives produce auditory hallucinations through NMDA antagonism, which impairs sensory gating mechanisms and can lead to disinhibited firing in temporal lobe auditory regions. Deliriants such as diphenhydramine produce particularly vivid and realistic auditory hallucinations through muscarinic acetylcholine receptor antagonism, which profoundly disrupts the neurotransmitter systems involved in reality testing.
Auditory hallucinations occur across many substance classes but with qualitatively different characters. Psychedelics (LSD, psilocybin, DMT) tend to produce musical and abstract auditory hallucinations, often pleasant and complex.Dissociatives (ketamine, DXM, PCP) can generate immersive sonic environments, particularly during dissociative holes.Deliriants (diphenhydramine, datura) produce the most realistic and often disturbing auditory hallucinations — convincing phantom conversations and environmental sounds that are difficult to distinguish from reality.Cannabis at high doses, particularly edibles, can produce mild auditory hallucinations.Stimulant psychosis from prolonged use of amphetamines or cocaine can generate persecutory auditory hallucinations.
While psychedelic auditory hallucinations are generally benign and often enjoyable, deliriant-induced auditory hallucinations deserve serious caution — they can be indistinguishable from reality and may provoke dangerous behavioral responses. Stimulant-induced auditory hallucinations (especially persecutory voices) are a sign of psychosis and indicate a medical emergency requiring cessation of use and professional help. Individuals with a personal or family history of schizophrenia or psychotic disorders should exercise extreme caution with any substance that produces auditory hallucinations, as these effects may trigger or exacerbate underlying conditions. If hallucinated voices become commanding or frightening, this is a sign to seek immediate support.
Auditory hallucination can manifest at varying intensities depending on the dose of Ibogaine and individual sensitivity. The following levels describe the typical progression of this effect.
Vague, ambiguous sounds at the edge of perception — faint whispers, phantom notification sounds, or barely audible music that one cannot be sure is real.
Identifiable sounds with no source — distinct musical snippets, recognizable words or phrases, phantom environmental sounds like a ringing phone.
Clear and detailed auditory hallucinations — full melodies, conversational fragments, or rich environmental soundscapes; one can usually still distinguish them from reality.
Complex, vivid auditory experiences — entire songs with lyrics, coherent conversations, or immersive sonic environments that are difficult to distinguish from real sounds.
Complete auditory hallucination dominance — the hallucinated soundscape is indistinguishable from reality; real and imagined sounds merge into a single perceptual stream.
Ibogaine is believed to produce its psychedelic effects from its binding efficacy at the 5-HT2A receptor. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
Ibogaine is rapidly metabolized in the human body into noribogaine. Noribogaine acts as a serotonin reuptake inhibitor. It also acts as a moderate κ-opioid receptor agonist and weak µ-opioid receptor agonist It is possible that the action of ibogaine at the kappa opioid receptor may contribute significantly to the psychoactive effects. Salvia divinorum is another plant recognized for its strong hallucinogenic properties; it contains the chemical salvinorin A which is also a highly selective kappa opioid agonist.
Both ibogaine and noribogaine have a plasma half-life of around two hours in rats, although the half-life of noribogaine is slightly longer than that of the parent compound. It is proposed that ibogaine is deposited in fat and metabolized into noribogaine as it is released. After ibogaine ingestion in humans, noribogaine shows higher plasma levels than ibogaine and is detected for a longer period than ibogaine. Noribogaine is also more potent than ibogaine in rat drug discrimination assays when tested for the subjective effects of ibogaine.
Ibogaine also has activity as an NMDA receptor antagonist.
Ibiogaine can be found within a variety of natural sources which are primarily found on the African continent.
The most common of these are listed below.
Research suggests that ibogaine may be useful in treating dependence on other substances such as alcohol, methamphetamine, and nicotine and may affect compulsive behavioral patterns not involving substance abuse or chemical dependence. Researchers note that there remains a "need for systematic investigation in a conventional clinical research setting."
Many users of ibogaine report experiencing visual phenomena during a waking dream state, such as instructive replays of life events that led to their addiction, while others report therapeutic shamanic visions that help them conquer the fears and negative emotions that might drive their addiction. It is proposed that intensive counseling, therapy and aftercare during the interruption period following treatment is of significant value. Some individuals require a second or third treatment session with ibogaine over the course of the next 12 to 18 months. A minority of individuals relapse completely into opiate addiction within days or weeks. A comprehensive article on the subject of ibogaine therapy detailing the procedure, effects and aftereffects is found in "Ibogaine in the Treatment of Chemical Dependence Disorders: Clinical Perspectives".
There is also evidence that this type of treatment works with LSD, which has been shown to have a therapeutic effect on alcoholism. Both ibogaine and LSD appear to be effective for encouraging introspection and giving the user occasion to reflect on the sources of their addiction, while also producing an intense, transformative experience that can put established patterns of behaviour into perspective; ibogaine has the added benefit of preventing withdrawal effects.
Ibogaine has been associated with life-threatening heart complications, such as QT prolongation. It can be taken safely, but only under the supervision of trained medical professionals. -not habit-forming, and the desire to use it can actually decrease with regular consumption. Like most psychedelics, it is most often thought to be self-regulating.
Ibogaine is unregulated and unlicensed in most countries. Some exceptions are listed below.
Brazil: On January 14, 2016, Ibogaine was legalized for prescription use.
Canada: Ibogaine is prescription drug since 2017.
Germany: Ibogaine is not a controlled substance under the BtMG (Narcotics Act) or the NpSG (New Psychoactive Substances Act). Technically it would fall under the definition of a medicine by §2 AMG (Medicines Act) because it induces a pharmacological effect. By a decision of the European Court of Justice, this definition was declared ineffective because it was not compatible with EU law. Ibogaine can be considered unregulated.
Mexico: As of 2009, ibogaine is unregulated.
New Zealand: Ibogaine was gazetted in 2009 as a non-approved prescription medicine.
Norway: Ibogaine is illegal (as are all tryptamine derivatives).
Sweden: Ibogaine is a schedule I drug.
Switzerland: Ibogaine is a controlled substance specifically named under Verzeichnis D.
United Kingdom: It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
United States: Ibogaine is classified as a Schedule I drug, and is not currently approved for addiction treatment (or any other therapeutic use) because of its hallucinogenic, cardiovascular and possibly neurotoxic side effects, as well as the scarcity of safety and efficacy data in human subjects.
Responsible use
Tryptamines
Entheogens
Psychedelics
Ibogaine (Wikipedia)
Ibogaine (Erowid Vault)
Ibogaine (TiHKAL / Isomer Design)
Ibogaine (Drugs-Forum)
Discussion
The Big & Dandy Ibogaine Thread (Bluelight)
Mačiulaitis, R., Kontrimavičiūtė, V., Bressolle, F. M. M., & Briedis, V. (2008). Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review. Human & experimental toxicology, 27(3), 181-194. https://doi.org/10.1177/0960327107087802.
Koenig, X., & Hilber, K. (2015). The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules, 20(2), 2208-2228. https://doi.org/10.3390/molecules20022208
Ibogaine can be administered via oral. The route of administration can influence both the onset and intensity of auditory hallucination.
The intensity of auditory hallucination depends heavily on the dose of Ibogaine. Effects like auditory hallucination are typically reported at common to strong doses. Below is the full dosage chart for Ibogaine.
Warning
Realistic auditory hallucinations, especially from deliriants or stimulant psychosis, can be indistinguishable from reality and may prompt dangerous behavior. Hearing commanding or persecutory voices is a sign of acute psychosis requiring immediate medical attention. Individuals with a history of psychotic disorders should avoid substances that produce this effect.
Yes. Auditory hallucination is a documented auditory effect of Ibogaine. Auditory hallucination is the perception of sounds that have no external source — hearing music, voices, environmental noises, or abstract sonic phenomena that exist entirely within the mind. These range from faint, ambiguous whispers at the edge of perception to fully formed, complex musical compositions or conversational speech that can feel completely real and externally sourced.
Effects like auditory hallucination are typically reported at common doses and above. A common oral dose of Ibogaine is 15–22 mg/kg of body weight.
Other substances documented to produce auditory hallucination include Diphenhydramine, Datura, Dextromethorphan, Methamphetamine, 1cP-MiPLA, and 35 more.